Prosus Ventures leads $5 million seed investment in AI hiring firm Qureos

Fabricio Bloisi
Fabricio Bloisi
0Comments

Prosus Ventures has announced a US$5 million investment in Qureos, an AI-powered hiring platform. The funding round was led by Prosus Ventures, with participation from Salica Oryx Fund and other strategic investors.

Qureos offers a system that brings together sourcing, screening, and interviewing into one platform. This approach aims to shorten hiring timelines for enterprises and recruitment teams, turning recruitment into what the company describes as a competitive advantage.

Robin Voogd, Head of Middle East Investments at Prosus Ventures, said: “Hiring at scale is one of the most operationally complex challenges facing modern organizations. Qureos has built a practical, end-to-end system that replaces fragmented recruitment workflows with a single, intelligent platform. By unifying sourcing, screening, and interviewing, the company enables employers to hire faster without sacrificing quality, a critical advantage in high-growth, time-sensitive markets.”

The Qureos platform features an intelligent assistant named Iris that supports role matching and candidate screening. It also helps candidates prepare for interviews while aiming to improve experiences for both employers and applicants.

Currently used by more than 1,000 enterprise and public sector organizations—including Qatar Airways, Dubai Economy and Tourism, BAAN Holdings, and Union Properties—Qureos tailors its platform to regional requirements such as localization and nationalization policies across Gulf Cooperation Council (GCC) countries. The system can be integrated with existing Applicant Tracking Systems (ATS) or Human Resource Information Systems (HRIS), or function independently.

According to the announcement, the new funds will be directed toward further developing Qureos’s AI features and expanding its reach through partnerships with enterprises and agencies globally.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.